First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
A veteran in cell therapy and oncology commercialisation
Drug formulations and biologics make impressive gains
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
